Screening Platform for Clinical Trials in Advanced Colorectal Cancer (SPECTAcolor)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01723969|
Recruitment Status : Active, not recruiting
First Posted : November 8, 2012
Last Update Posted : June 21, 2019
The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.
Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.
A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.
The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer Advanced Colorectal Cancer||Genetic: Tumour markers testing|
|Study Type :||Observational|
|Actual Enrollment :||668 participants|
|Official Title:||Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer "SPECTAcolor"|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||February 2020|
Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
Genetic: Tumour markers testing
Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
- Tumour markers assessment [ Time Frame: Within 1 week after patient registration ]Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01723969
|Study Chair:||Gunnar Folprecht, MD||Universitaetsklinikum Carl Gustav Carus, Dresden, DE|
|Study Chair:||Sabine Tejpar, MD, PhD||U.Z. Leuven - Campus Gasthuisberg, Leuven, BE|
|Study Chair:||Daniela Aust, MD||Universitaetsklinikum Carl Gustav Carus, Dresden, DE|